Oxford Bioscience Partners - Boston, MA

Oxford Bioscience Partners (OBP), established in 1992, is a venture capital firm that provides equity financing and management assistance to emerging, entrepreneurial-driven companies within the life sciences and healthcare sectors. Experienced partners, who bring together deep domain knowledge in life sciences, have established a proven track record of identifying, validating and backing emerging trends and technologies. While willing to consider an investment in a company at almost any stage, OBP brings unique value and expertise to early-stage situations. With approximately $1B of committed capital under management, OBP has invested in over 140 life science companies worldwide, and has successfully leveraged the extensive research, operating, and financial expertise and experience of its team of investment professionals.

Oxford's team of investment professionals has a history of backing leading life science companies, including: SIRNA (acquired by Merck); SOLEXA (acquired by Illumina); ALANTOS (acquired by Amgen); TRUBION (NASDAQ: TRBN); HYPNION (acquired by Eli Lilly); HUMAN GENOME SCIENCES (NASDAQ: HGSI); POWDERMED (acquired by Pfizer); ACADIA (NASDAQ; ACAD); PVT (acquired by Edwards); EXELIXIS (NASDAQ: EXEL); SOSEI (Nikkei: 4565); COHESIVE (acquired by Thermo Fisher); IMPELLA (acquired by Abiomed); STRATAGENE (acquired by Agilent); SANTHERA (SWX:SANN); EXONHIT (EURONEXT: ALEHT); INVERNESS MEDICAL (NYSE: IMA)



Newsletter
 
 
 
 



June 26, 2009
Santhera Enters Agreement with Columbia University to Investigate Additional Potential of Catena® in MELAS -- more

June 24, 2009
Santhera and NIH Collaborate To Evaluate Catena® in Primary Progressive Multiple Sclerosis -- more

June 22, 2009
Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration -- more

June 1, 2009
Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL) -- more

May 29, 2009
AV-951 Demonstrates Prolonged Progression-Free Survival and Excellent Safety Profile in Patients with Advanced Kidney Cancer -- more

May 27, 2009
ExonHit and Institut Gustave Roussy Announce the Signing of a License Agreement for Novel Breast Cancer Diagnostic Assay -- more

May 21, 2009
Pathway Medical Technologies Closes $42.5M Series D Financing; Announces New Investment From WRF -- more

May 20, 2009
Ceres Yield Results: Energy Crop Benefits are Greatly Underestimated -- more

Click here to view more articles